Thrombotic microangiopathy
MONDO:0019737The syndromes of microangiopathic hemolytic anemia, thrombocytopenia, and variable signs of organ impairment, due to platelet aggregation in the microcirculation.
154 clinical trials for this condition and its sub-types, 26 tagged with Thrombotic microangiopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Thrombotic microangiopathy
-
Thrombocytopenic purpura 8 trials · 116 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types Sub-types →
-
Atypical hemolytic-uremic syndrome 19 trials
4 sub-types
Most studied deeper sub-types
-
New pill shows promise for rare blood disorder aHUS
Disease control CompletedThis study tested a new oral medication called iptacopan in 34 adults with a rare disease called atypical hemolytic uremic syndrome (aHUS), which causes blood clots, low platelets, and kidney damage. The goal was to see if the drug could improve blood counts and kidney function w…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for stem cell transplant patients with dangerous blood clotting disorder
Disease control CompletedThis study tested a drug called ravulizumab in people aged 12 and older who developed a serious blood clotting condition (thrombotic microangiopathy) after a stem cell transplant. The goal was to see if the drug could prevent death or worsening of the condition over 26 weeks. Par…
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for rare post-transplant complication in kids
Disease control CompletedThis study tested a drug called ravulizumab in 41 children who developed a serious blood clotting problem (TMA) after a stem cell transplant. The goal was to see if the drug could help control the condition and improve blood counts and kidney function. The treatment lasted 26 wee…
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug shows promise for stem cell transplant complication
Disease control CompletedThis pilot study tested a drug called pegcetacoplan in 12 adults who developed a serious blood clotting condition (TA-TMA) after a stem cell transplant. The goal was to see how the drug moves through the body, if it helps, and if it is safe. Researchers measured drug levels and m…
Phase 2 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New blood test could speed up Life-Saving treatment for HUS patients
Diagnosis CompletedThis study tested a new blood test designed to quickly determine whether the complement system is involved in a serious kidney condition called thrombotic microangiopathy (TMA). The test measures complement deposits on cells in a lab sample. Researchers compared test results to h…
Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Can Real-World data unlock clues to a deadly Post-Transplant complication?
Knowledge-focused CompletedThis study looks back at medical records of children and adults who developed a serious blood-clotting condition called thrombotic microangiopathy (TMA) within a year after a stem cell transplant. Researchers aim to understand survival rates and causes of death in these patients,…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC